Glaxosmithkline Pharmaceuticals Ltd Share Price

2,343.15
(-1.60%)
Dec 6, 2024|03:31:16 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open2,382.1
  • Day's High2,399
  • 52 Wk High3,088
  • Prev. Close2,381.2
  • Day's Low2,333
  • 52 Wk Low 1,661.35
  • Turnover (lac)1,736.69
  • P/E50.6
  • Face Value10
  • Book Value130.72
  • EPS46.98
  • Mkt. Cap (Cr.)39,694.37
  • Div. Yield1.35
View All Historical Data
No Records Found

Glaxosmithkline Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

2,382.1

Prev. Close

2,381.2

Turnover(Lac.)

1,736.69

Day's High

2,399

Day's Low

2,333

52 Week's High

3,088

52 Week's Low

1,661.35

Book Value

130.72

Face Value

10

Mkt Cap (₹ Cr.)

39,694.37

P/E

50.6

EPS

46.98

Divi. Yield

1.35

Glaxosmithkline Pharmaceuticals Ltd Corporate Action

29 Oct 2024

12:00 AM

Dividend

Dividend Amount: 12

Record Date: 07 Nov, 2024

arrow

17 May 2024

12:00 AM

AGM

Announcement Date: 17 May, 2024

arrow

24 Oct 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Glaxosmithkline Pharmaceuticals Ltd NEWS AND UPDATE

Top 10 stocks for today – 4th September 2024
4 Sep 2024|09:16 AM

Here are some of the stocks that may see significant price movement today: GIC Re, GSK Pharma, Godfrey Philips, etc.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Glaxosmithkline Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

08 Dec, 2024|03:17 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 750.00%

Foreign: 75.00%

Indian: 0.00%

Non-Promoter- 11.69%

Institutions: 11.69%

Non-Institutions: 13.30%

Custodian: 0.00%

Share Price

Glaxosmithkline Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

169.41

169.41

169.41

169.41

Preference Capital

0

0

0

0

Reserves

1,614.69

1,583.59

2,508.21

1,327.71

Net Worth

1,784.1

1,753

2,677.62

1,497.12

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

3,217.5

2,920.47

3,224.68

2,871.68

yoy growth (%)

10.17

-9.43

12.29

-1.07

Raw materials

-1,295.73

-1,249.36

-1,307.86

-1,240.75

As % of sales

40.27

42.77

40.55

43.2

Employee costs

-610.23

-616.16

-628.55

-523.39

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

761.86

625.82

646.99

523.78

Depreciation

-68.18

-78.6

-82.67

-37.98

Tax paid

-396.86

-166.53

-212.44

-189.59

Working capital

776.94

111.42

187.45

-365.58

Other operating items

View Cash Flow
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

10.17

-9.43

12.29

-1.07

Op profit growth

26.44

-9.21

29.5

21.07

EBIT growth

21.37

-3.66

24.68

12.53

Net profit growth

372.78

224.9

-68.73

4.51

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

3,453.71

3,251.72

3,278.03

2,925.6

3,224.38

Excise Duty

0

0

0

0

0

Net Sales

3,453.71

3,251.72

3,278.03

2,925.6

3,224.38

Other Operating Income

0

0

0

0

0

Other Income

122.59

103.71

1,401.31

181.46

79.01

Glaxosmithkline Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,804.85

157.54,34,195.65863.290.755,123.6798.33

Divis Laboratories Ltd

DIVISLAB

6,130.75

88.091,61,829.655180.492,302513.62

Cipla Ltd

CIPLA

1,477.4

28.591,21,053.041,178.160.873,969.86360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,332.5

69.571,13,812.44600.832,376222.38

Mankind Pharma Ltd

MANKIND

2,586.45

52.351,04,937.42634.4302,529.74269.23

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Glaxosmithkline Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Independent Director

D Sundaram

Company Sec. & Compli. Officer

A A Nadkarni

Independent Director

P V Bhide

Independent Director

A N Roy

Non Executive Director

Subesh Williams

Chairperson

Renu S Karnad

Independent Director

Sunita Maheshwari

Independent Director

Manu Anand

Managing Director

Bhushan Akshikar

Whole Time Director & CFO

J. Chandy

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Reports by Glaxosmithkline Pharmaceuticals Ltd

Summary

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is headquartered in Mumbai and it has six branch offices, a manufacturing facility at Nashik in Maharashtra, 22 contract manufacturing organisations (CMOs) with regional and sales hubs across India. The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.The Companys portfolio includes General Medicines, Vaccines and Specialty medicines that help prevent and treat disease. Their prescription medicines range across therapeutic areas, such as Anti-Infectives, Dermatology, Gynaecology, Diabetes, Oncology, Cardiovascular Disease and Respiratory Diseases. They also offer a range of vaccines, for the prevention of Hepatitis A, Hepatitis B, Invasive Disease caused by H, Influenza, Chickenpox, Diphtheria, Pertussis, Tetanus, Rotavirus, Cervical Cancer and Others. They have two manufacturing units in India, located at Nashik and Thane. Also, they have a clinical development centre in Bangalore. GlaxoSmithKline Pharma Limited was incorporated in November 13, 1924. During year 1956, the Company began primary production of vaccines at Worli. In the year 1960, the company started manufacturing Infant foods at milk drying plant at Aligarh. They also opened manufacturing facility for pharmaceuticals in Mumbai. In 1961, the Company started manufactu
Read More

Company FAQs

What is the Glaxosmithkline Pharmaceuticals Ltd share price today?

The Glaxosmithkline Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹2343.15 today.

What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glaxosmithkline Pharmaceuticals Ltd is ₹39694.37 Cr. as of 06 Dec ‘24

What is the PE and PB ratio of Glaxosmithkline Pharmaceuticals Ltd?

The PE and PB ratios of Glaxosmithkline Pharmaceuticals Ltd is 50.6 and 24.05 as of 06 Dec ‘24

What is the 52 Week High and Low of Glaxosmithkline Pharmaceuticals Ltd?

The 52-week high/low is the highest and lowest price at which a Glaxosmithkline Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Glaxosmithkline Pharmaceuticals Ltd is ₹1661.35 and ₹3088 as of 06 Dec ‘24

What is the CAGR of Glaxosmithkline Pharmaceuticals Ltd?

Glaxosmithkline Pharmaceuticals Ltd's CAGR for 5 Years at 7.63%, 3 Years at 10.18%, 1 Year at 40.76%, 6 Month at -3.71%, 3 Month at -15.38% and 1 Month at -8.22%.

What is the shareholding pattern of Glaxosmithkline Pharmaceuticals Ltd?

The shareholding pattern of Glaxosmithkline Pharmaceuticals Ltd is as follows:
Promoters - 75.00 %
Institutions - 11.70 %
Public - 13.30 %

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2024, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp